Monitor first-day trading volume and price action for signs of demand. The $301.5M raise provides a multi-year cash runway for pipeline development, but as a clinical-stage company with no approved products, near-term catalysts depend on clinical trial data readouts for sutacimig and HMB-002.
Price Chart
Executive Summary
Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an underwriter option for an additional 2.5125M shares. The stock begins trading on Nasdaq May 1, 2026 under ticker COAG. This is a dilutive event for existing holders but provides capital to advance its clinical pipeline in blood coagulation disorders.
Key Financial Metrics
Key Facts
- IPO priced at $18.00 per share for 16,750,000 shares
- Gross proceeds of approximately $301.5 million before expenses
- Underwriters have a 30-day option to purchase up to 2,512,500 additional shares
- Trading begins on Nasdaq Global Select Market on May 1, 2026 under ticker COAG
- Goldman Sachs, Jefferies, and Evercore ISI are joint book-running managers
- Offering expected to close on or about May 4, 2026
- Company is a clinical-stage biotech focused on blood coagulation disorders
Financial Impact
Gross proceeds of ~$301.5M from IPO, representing significant capital infusion for a clinical-stage biotech
Risk Factors
- Dilution for existing shareholders from the 16.75M share offering
- Clinical-stage company with no approved products or revenue
- Potential for underwriters to exercise overallotment option, adding further dilution
- Market conditions may affect post-IPO trading performance
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285621 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access